Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus

Diabetes Technology and Therapeutics

Volumn 13, Issue 12, 2011, Pages 1219-1227

  Schwartz, Sherwyn L ^a   Akinlade, Bola ^b   Klasen, Sally ^b   Kowalski, Donna ^b   Zhang, Wenhui ^b   Wilpshaar, Wim ^b  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b Astellas Pharma Global Development   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ASP 1941; CIPROFLOXACIN; COTRIMOXAZOLE; GLIPIZIDE; IPRAGLIFLOZIN; METFORMIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACKACHE; CONCENTRATION (PARAMETERS); CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; STEADY STATE; TOOTH PAIN; TREATMENT DURATION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSAMINE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; YOUNG ADULT;

EID: 82455213037     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0012     Document Type: Article

References (29)

1. Spellman CW: Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factors. J Am Osteopath Assoc 2009;109(5 Suppl):S8-S13.
2. Stanton C, Phillips P: Dietary dilemmas in diabetes. Aust Fam Physician 2005;34:455-458.
3. Brown DL, Brillon D: New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy. J Natl Med Assoc 1999;91:389-395.
4. Blonde L: State of diabetes care in the United States. Am J Manag Care 2007;13(Suppl 2):S36-S40. (Pubitemid 46651159)
5. Nissen SE, Wolski K: Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-1201.
6. Blonde L: Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med 2009;76(Suppl 5):S4-S11.
7. Cefalu WT, Richards RJ, Melendez-Ramirez LY: Redefining treatment success in type 2 diabetes mellitus: comprehensive targeting of core defects. Cleve Clin J Med 2009;76(Suppl 5):S39-S47.
8. Jabbour SA, Goldstein BJ: Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008;62:1279-1284. (Pubitemid 351977622)
9. Gerich JE: Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010;27:136-142.
10. Abdul-Ghani MA, DeFronzo RA: Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008;14:782-790.
11. Neumiller JJ, White JR Jr, Campbell RK: Sodium-glucose cotransport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-385.
12. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M: Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-526.
13. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M: Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-519.
14. Isaji M: SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int 2011;79(Suppl 120):S14-S19.
15. Kurosaki E, Tahara A, Yokono M, Yamajuku D, Takasu T, Imamura M, Funatsu T, Li Q: In vitro and in vivo pharmacological properties of ASP1941, a novel, potent and selective SGLT2 inhibitor [abstract 0570-P]. Presented at theAmerican Diabetes Association's 70th Scientific Sessions, June 25-29, 2010, Orlando, FL.
16. Veltkamp SA, Kadokura T, Krauwinkel WJJ, Smulders RA: ASP1941, a novel and selective SGLT2 inhibitor, stimulates urinary glucose excretion in healthy subjects [abstract 0565]. Presented at the American Diabetes Association's 70th Scientific Sessions, June 25-29, 2010, Orlando, FL.
17. Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Kageyama S: ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus [abstract 0075]. Presented at the American Diabetes Association's 70th Scientific Sessions, June 25-29, 2010, Orlando, FL.
18. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
19. Nair S, Wilding JP: Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42.
20. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD Trial Group: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-430.
21. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT: A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-1662.
22. Idris I, Donnelly R: Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009;11:79-88.
23. List FJ, Woo V, Morales E, Tang W, Fiedorek FT: Sodiumglucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-657.
24. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF: Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-2224.
25. Rosenstock J, Polidori D, Zhao Y, Sha S, Arbit D, Usiskin K, Capuano G, Canovatchel W: Canagliflozin, an inhibitor of sodium glucose co-transporter 2, improves glycaemic control, lowers body weight, and improves beta cell function in subjects with type 2 diabetes on background metformin [abstract 873]. Presented at the 46th EASD Meeting, September 20-24, 2010, Stockholm.
26. Calado J: Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. IDrugs 2009;12:785-798.
27. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-2233.
28. Klein SK, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG; American Diabetes Association; North American Association for the Study of Obesity; American Society for Clinical Nutrition: Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004;27:2067-2073.
29. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79. (Pubitemid 36026281)